|
시장보고서
상품코드
1761162
세계의 바이오의약품 수탁 제조 시장 : 시장 규모, 예측, 점유율, 동향, 성장기회 분석 보고서 - 제품 유형별, 공급원별, 용도별, 치료 분야별, 지역별(2021-2031년)Biopharmaceutical Contract Manufacturing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Source, Application, Therapeutic Area, and Geography |
||||||
바이오의약품 수탁 제조 시장 규모는 2024년 409억 9,000만 달러로 평가되었고, 2031년에는 1,010억 5,000만 달러로 성장할 것으로 예측되며, 2025-2031년 CAGR 13.8%로 예측되고 있습니다. 생물제제에 대한 수요 증대, 비용효율 및 유연성에 대한 수요 증대는 바이오의약품 수탁 제조 시장 규모의 확대에 기여하는 주목할 만한 요인입니다. 그러나 예산의 핍박과 경제의 불확실성이 바이오의약품 수탁 제조 시장의 성장을 가로막고 있습니다.
단일클론항체, 유전자 치료, 세포 기반 치료는 보다 혁신적이고 합리적인 제조 공정의 필요성을 창출하고 있습니다. 그 결과 제조 수탁 기관(CMO)은 연속 제조, 자동화, 인공지능(AI), 프로세스 분석기술(PAT) 등 선진 기술을 채택해 생산능력을 강화하고 바이오의약품 수요 증가에 대응하는 움직임이 가속화되고 있습니다. 연속 제조는, 생물 제제의 연속 생산을 가능하게 해, 일관성, 스피드, 효율을 높이는 것으로부터, 바이오 의약품 업계에서 급속히 보급되고 있습니다. 이 프로세스를 통해 제조 공정 간의 다운타임이 단축되고 중간 저장의 필요성이 최소화되므로 제조 비용이 대폭 절감됩니다. 베이커 매켄지의 보고서에 따르면, 연속 제조는 생물 제제의 제조 비용을 30% 절감할 수 있습니다. 노바티스와 화이자는 대규모 생물학적 제제 제조에 연속 제조를 도입하고 있는 대기업 중 하나로, 업무 효율 개선과 비용 절감에 효과적임을 보여줍니다.
인공지능(AI)은 공정 최적화, 예지보전, 품질관리에도 이용할 수 있습니다. AI 기반 도구는 방대한 양의 생산 데이터를 실시간으로 분석해 잠재적인 문제가 발생하기 전에 파악하고 생산 프로세스 전체를 통해 최적의 상태를 확보할 수 있습니다. 이 기술은 CMO가 다운타임을 최소화하고 수율을 향상시키는 데 도움이 됩니다. 코그니잔트와 같은 기업은 이미 AI를 사용하여 제조 프로세스의 잠재적인 오류를 예측하고 의사결정을 개선하고 있습니다. 게다가 프로세스 분석 기술(PAT)은, 중요한 프로세스 파라미터의 실시간 모니터링과 제어를 가능하게 해, 생물 제제의 대규모 배치 전체에서 일관된 품질을 보증합니다. PAT를 통합함으로써 제조업체는 제조 공정의 빠른 단계에서 편차를 검출하고 결함이나 부정합을 방지하기 위해 실시간으로 조정할 수 있습니다. 그 결과 제품의 품질이 향상되고 리소스를 보다 효율적으로 사용할 수 있게 되어 시간과 비용 모두 절감됩니다. 따라서 연속 제조, 자동화, AI, PAT 등 고도의 제조기술 채택이 증가하고 있는 것은 향후 수년간 바이오의약품 수탁 제조 시장 성장에 기여할 것으로 예상됩니다.
치료 영역 기반 인사이트
치료 분야에 따라 바이오의약품 수탁 제조 시장은 종양학, 자가면역질환, 호흡기질환, 대사질환, 신경학, 감염증 등으로 구분됩니다. 2024년 바이오의약품 수탁 제조 시장 점유율은 암 분야가 최대였습니다. 암은 여전히 세계 사인의 1위이기 때문에 선진적인 암 치료에 대한 요구가 높아지고 있습니다. 세계보건기구(WHO)에 따르면 2022년에는 전 세계적으로 2,000만 명의 신규 암 환자와 970만 명의 암 관련 사망이 보고되었습니다. 이 수요는 주로 생물학적 제제의 개발에 의해 초래되고 있으며, 생물학적 제제의 제조에는 복잡한 세포배양 시스템과 엄격한 품질관리 조치가 필요하기 때문에 많은 제약기업에서 제조위탁처로의 아웃소싱은 실행 가능한 솔루션이 되고 있습니다. 키트루다는 2024년 294억 8,000만 달러의 매출액을 기록했으며, 암 생물학적 제제의 거대한 시장 잠재력을 부각시켰습니다. 또한 특히 Kymriah(tisagen lecleucel)나 Yescarta(axicabtagene ciloleucel) 등의 CAR-T 요법을 중심으로 한 개별화종양 치료에 대한 경향의 고조도 고도로 전문화된 수탁제조의 필요성에 박차를 가하고 있습니다. 이러한 치료에는 유전자 조작 면역세포의 생산이 필요하고, 세포 치료나 유전자 치료에 정통한 CMO에 대한 수요가 생겨, 바이오 의약품 수탁 제조 시장의 성장에 박차를 가하고 있습니다.
세계보건기구(WHO), 세계자가면역연구소(Global Autoimmune Institute 2022) 보고서, 국제당뇨병연합(International Diabetes Federation) 등은 바이오의약품 수탁 제조 시장 보고 작성 시 참조한 1차 및 2차 정보입니다.
목차
제1장 서론
제2장 주요 요약
- 애널리스트 시장 전망
제3장 조사 방법
- 2차 조사
- 1차 조사
- 가설의 책정
- 거시경제 요인분석
- 파운데이션 수치의 개발
- 데이터의 삼각측량
- 국가 레벨 데이터
- 가정과 한계
제4장 바이오의약품 수탁 제조 시장의 정세
- PEST 분석
제5장 바이오의약품 수탁 제조 시장 : 주요 시장 역학
- 바이오의약품 수탁 제조 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 생물 제제에 대한 수요 증가
- 비용 효율성 및 유연성에 대한 요구 증가
- 시장 성장 억제요인
- 예산의 부족 및 경제의 불확실성
- 시장 기회
- 맞춤형 의료에 대한 수요 증가
- 향후 동향
- 첨단 제조 기술
- 성장 촉진요인 및 억제요인의 영향
제6장 세계의 바이오의약품 수탁 제조 시장 : 시장 분석
- 바이오의약품 수탁 제조 시장의 수익(2021-2031년)
- 바이오의약품 수탁 제조 시장 예측 분석
제7장 바이오의약품 수탁 제조 시장 분석 : 제품 유형별
- 생물제제
- 바이오시밀러
제8장 바이오의약품 수탁 제조 시장 분석 : 공급원별
- 미생물
- 포유류
제9장 바이오의약품 수탁 제조 시장 분석 : 용도별
- 상업용
- 임상용
제10장 바이오의약품 수탁 제조 시장 분석 : 치료 분야별
- 암 영역
- 자가면역질환
- 호흡기 질환
- 대사질환
- 신경학
- 감염증
- 기타
제11장 바이오의약품 수탁 제조 시장 : 지역별 분석
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양의 기타 국가
- 중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
- 중남미
- 브라질
- 아르헨티나
- 기타 중남미
제12장 경쟁 구도
- 주요 기업의 히트맵 분석
- 기업의 포지셔닝 및 집중도
제13장 업계 정세
- 사업 확대
- 신제품 개발
- 합병 및 인수
- 파트너십
- 기타 사업 전략
제14장 기업 프로파일
- Boehringer Ingelheim International GmbH
- Lonza Group AG
- Samsung Biologics Co Ltd
- Merck KGaA
- AbbVie Inc
- WuXi Biologics Inc
- Ajinomoto Co Inc
- Cytiva
- AGC Biologics AS
제15장 부록
AJY 25.07.10The biopharmaceutical contract manufacturing market size is expected to grow from US$ 40.99 billion in 2024 to US$ 101.05 billion by 2031; it is projected to register a CAGR of 13.8% during 2025-2031. Rising demand for biologics and increasing demand for cost efficiency and flexibility are noteworthy factors contributing to the expansion of the biopharmaceutical contract manufacturing market size. However, the tightened budget and economic uncertainty hinder the biopharmaceutical contract manufacturing market growth.
Monoclonal antibodies, gene therapies, and cell-based treatments have created the need for more innovative, streamlined manufacturing processes. As a result, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies such as continuous manufacturing, automation, artificial intelligence (AI), and process analytical technologies (PAT) to enhance production capabilities and meet the growing demand for biopharmaceuticals. Continuous manufacturing is rapidly gaining traction in the biopharmaceutical industry as it allows the uninterrupted production of biologics, providing greater consistency, speed, and efficiency. This process reduces downtime between production runs and minimizes the need for intermediate storage, significantly reducing production costs. According to a Baker McKenzie report, continuous manufacturing can reduce the cost of biologic production by 30%. Novartis and Pfizer are among the major companies implementing continuous manufacturing for large-scale biologic production, demonstrating its effectiveness in improving operational efficiency and reducing costs.
Artificial intelligence (AI) can also be used for process optimization, predictive maintenance, and quality control. AI-based tools can analyze vast amounts of production data in real-time, identifying potential issues before they arise and ensuring optimal conditions throughout the production process. This technology helps CMOs minimize downtime and improve yield rates. Companies such as Cognizant are already using AI to predict potential failures in manufacturing processes and improve decision-making. Furthermore, process analytical technologies (PAT) enable real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By integrating PAT, manufacturers can detect variations early in the production process and adjust in real-time to prevent defects or inconsistencies. This results in higher-quality products and more efficient use of resources, reducing both time and cost. Therefore, the increasing adoption of advanced manufacturing technologies such as continuous manufacturing, automation, AI, and PAT is expected to contribute to the growth of the biopharmaceutical contract manufacturing market in the coming years.
Therapeutic Area-Based Insights
Based on the therapeutic area, the biopharmaceutical contract manufacturing market is segmented into oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. The oncology segment held the largest biopharmaceutical contract manufacturing market share in 2024. As cancer remains a leading cause of death globally, it drives the need for advanced cancer treatments. According to the World Health Organization (WHO), 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. This demand is primarily driven by the development of biologics and the production of biologics involves complex cell culture systems and stringent quality control measures, making outsourcing to contract manufacturers a viable solution for many pharmaceutical companies. Keytruda generated US$ 29.48 billion in sales in 2024, highlighting the immense market potential of oncology biologics. Additionally, the increasing trend toward personalized oncology treatments, particularly with CAR-T therapies such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), has also fueled the need for highly specialized contract manufacturing. These treatments require the production of genetically modified immune cells, which creates the demand for CMOs with expertise in cell and gene therapies, thereby fueling the biopharmaceutical contract manufacturing market growth.
World Health Organization (WHO), Global Autoimmune Institute 2022 report, and International Diabetes Federation are among the primary and secondary sources referred to while preparing the biopharmaceutical contract manufacturing market report.
Table Of Contents
1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Analyst Market Outlook
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 3.3 Assumptions and Limitations
4. Biopharmaceutical Contract Manufacturing Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
5. Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
- 5.1 Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
- 5.2 Market Drivers:
- 5.2.1 Rising Demand for Biologics
- 5.2.2 Increasing Demand for Cost Efficiency and Flexibility
- 5.3 Market Restraints
- 5.3.1 Tightened Budget and Economic Uncertainty
- 5.4 Market Opportunities
- 5.4.1 Increasing Demand for Personalized Medicine
- 5.5 Future Trends
- 5.5.1 Advanced Manufacturing Technologies
- 5.6 Impact of Drivers and Restraints:
6. Biopharmaceutical Contract Manufacturing Market - Global Market Analysis
- 6.1 Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2021-2031
- 6.2 Biopharmaceutical Contract Manufacturing Market Forecast Analysis
7. Biopharmaceutical Contract Manufacturing Market Analysis - by Product Type
- 7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 7.2 Biosimilar
- 7.2.1 Overview
- 7.2.2 Biosimilar: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8. Biopharmaceutical Contract Manufacturing Market Analysis - by Source
- 8.1 Microbial
- 8.1.1 Overview
- 8.1.2 Microbial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 8.2 Mammalian
- 8.2.1 Overview
- 8.2.2 Mammalian: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9. Biopharmaceutical Contract Manufacturing Market Analysis - by Application
- 9.1 Commercial
- 9.1.1 Overview
- 9.1.2 Commercial: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 9.2 Clinical
- 9.2.1 Overview
- 9.2.2 Clinical: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
10. Biopharmaceutical Contract Manufacturing Market Analysis - by Therapeutic Area
- 10.1 Oncology
- 10.1.1 Overview
- 10.1.2 Oncology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2 Autoimmune Disorders
- 10.2.1 Overview
- 10.2.2 Autoimmune Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3 Respiratory Disorders
- 10.3.1 Overview
- 10.3.2 Respiratory Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.4 Metabolic Disorders
- 10.4.1 Overview
- 10.4.2 Metabolic Disorders: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5 Neurology
- 10.5.1 Overview
- 10.5.2 Neurology: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.6 Infectious Diseases
- 10.6.1 Overview
- 10.6.2 Infectious Diseases: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
- 10.7 Others
- 10.7.1 Overview
- 10.7.2 Others: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
11. Biopharmaceutical Contract Manufacturing Market - Geographical Analysis
- 11.1 North America
- 11.1.1 North America Biopharmaceutical Contract Manufacturing Market Overview
- 11.1.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.1.2.1 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.1.2.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.1.2.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.1.2.4 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.1.3 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.1.3.1 United States: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.1.1 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.1.2 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.1.3 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.1.4 United States: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.1.3.2 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.2.1 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.2.2 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.2.3 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.2.4 Canada: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.1.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.1.3.3.1 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.1.3.3.2 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.1.3.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.1.3.3.4 Mexico: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.1.3.1 United States: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2 Europe
- 11.2.1 Europe Biopharmaceutical Contract Manufacturing Market Overview
- 11.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.2.2.1 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.2.2.2 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.2.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.2.2.4 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.2.3 Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.2.3.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.1.1 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.1.2 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.1.3 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.1.4 Germany: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.2.1 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.2.2 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.2.3 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.2.4 United Kingdom: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.3 France: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.3.1 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.3.2 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.3.3 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.3.4 France: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.4 Italy: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.4.1 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.4.2 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.4.3 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.4.4 Italy: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.5 Spain: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.5.1 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.5.2 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.5.3 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.5.4 Spain: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.6 Rest of Europe: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.2.3.6.1 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.2.3.6.2 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.2.3.6.3 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.2.3.6.4 Rest of Europe: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.2.3.1 Germany: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3 Asia Pacific
- 11.3.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Overview
- 11.3.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.3.2.1 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.3.2.2 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.3.2.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.3.2.4 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.3.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.3.3.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.1.1 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.1.2 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.1.3 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.1.4 China: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.2 Japan: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.2.1 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.2.2 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.2.3 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.2.4 Japan: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.3 India: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.3.1 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.3.2 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.3.3 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.3.4 India: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.4 Australia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.4.1 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.4.2 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.4.3 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.4.4 Australia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.5 South Korea: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.5.1 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.5.2 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.5.3 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.5.4 South Korea: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.6 Rest of APAC: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.3.3.6.1 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.3.3.6.2 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.3.3.6.3 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.3.3.6.4 Rest of APAC: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.3.3.1 China: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4 Middle East & Africa
- 11.4.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Overview
- 11.4.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.4.2.1 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.4.2.2 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.4.2.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.4.2.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.4.3 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.4.3.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.1.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.1.2 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.1.3 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.1.4 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.2 South Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.2.1 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.2.2 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.2.3 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.2.4 South Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.3.1 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.3.2 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.3.3 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.3.4 United Arab Emirates: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.4.3.4.1 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.4.3.4.2 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.4.3.4.3 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.4.3.4.4 Rest of Middle East & Africa: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.4.3.1 Saudi Arabia: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5 South & Central America
- 11.5.1 South & Central America Biopharmaceutical Contract Manufacturing Market Overview
- 11.5.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 11.5.2.1 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 11.5.2.2 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Source
- 11.5.2.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Application
- 11.5.2.4 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Therapeutic Area
- 11.5.3 South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast Analysis - by Country
- 11.5.3.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.1.1 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.1.2 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.1.3 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.1.4 Brazil: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5.3.2 Argentina: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.2.1 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.2.2 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.2.3 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.2.4 Argentina: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
- 11.5.3.3.1 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Product Type
- 11.5.3.3.2 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Source
- 11.5.3.3.3 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Application
- 11.5.3.3.4 Rest of South & Central America: Biopharmaceutical Contract Manufacturing Market Breakdown, by Therapeutic Area
- 11.5.3.1 Brazil: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
12. Competitive Landscape
- 12.1 Heat Map Analysis by Key Players
- 12.2 Company Positioning & Concentration
13. Industry Landscape
- 13.1 Overview
- 13.2 Expansion
- 13.3 New Product Development
- 13.4 Merger and Acquisition
- 13.5 Partnerships
- 13.6 Other Business Strategies
14. Company Profiles
- 14.1 Boehringer Ingelheim International GmbH
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Lonza Group AG
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Samsung Biologics Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 Merck KGaA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 AbbVie Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 WuXi Biologics Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 Ajinomoto Co Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Cytiva
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 AGC Biologics AS
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms
